CD274 and neoplasm: In TNBC, the SP142 assay is the companion diagnostic for atezolizumab [11, 12], the 73–10 assay is the companion diagnostic for avelumab (JAVELIN Solid Tumor study; NCT01772004l) [16], and the E1L3N assay is used as a laboratory-developed test [17]; these assays have different cut-off values for PD-L1 immunoreactivity and use different types of positive cells (tumor cells (TCs) vs. ICs).